Welcome to our dedicated page for Avidity Biosciences news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) is a pioneering biopharmaceutical company dedicated to revolutionizing RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™). Their innovative approach merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases that were previously unreachable with existing RNA therapies. They are at the forefront of developing therapies for serious genetic conditions, predominantly focusing on rare muscle diseases.
Avidity's leading clinical programs include:
- AOC 1001 (Del-desiran): Targeting Myotonic Dystrophy Type 1 (DM1), a disease with no approved therapies. Del-desiran has shown promising long-term data from the MARINA-OLE™ trial, demonstrating reversal of disease progression in patients. The global Phase 3 HARBOR™ trial is set to begin, with video hand opening time (vHOT) as the primary endpoint.
- AOC 1044: Aimed at Duchenne Muscular Dystrophy (DMD) with mutations amenable to exon 44 skipping. Recently, it achieved Rare Pediatric Disease and Orphan Drug designations from the FDA and EMA. Positive preliminary data has been reported from the Phase 1/2 EXPLORE44™ clinical trial.
- AOC 1020: Focused on Facioscapulohumeral Muscular Dystrophy (FSHD). Clinical data from the Phase 1/2 FORTITUDE™ trial is expected soon.
Avidity is also advancing its pipeline to include cardiology and immunology programs, aiming to target a broader range of diseases. The company has garnered support and collaborations with top-tier investors and strategic partners, enhancing its capability to deliver groundbreaking treatments.
With headquarters in San Diego, CA, Avidity Biosciences is committed to transforming lives through innovative RNA therapeutics. For more information, visit www.aviditybiosciences.com.
Avidity Biosciences announced the appointment of Tamar Thompson and Jean Kim to its Board of Directors, replacing Todd Brady and Michael Martin. Thompson brings expertise in health policy and market access, while Kim has over 20 years of experience in healthcare investment. The company aims to advance its Antibody Oligonucleotide Conjugates (AOCs) pipeline, with hopes of transforming treatments for serious diseases. Troy Wilson transitions to Chairman, highlighting leadership changes at a pivotal time for Avidity’s development.
Avidity Biosciences (RNA) announced significant pipeline updates and a new research collaboration with MyoKardia on January 8, 2021. Notably, AOC 1001 is set to enter Phase 1/2 studies for myotonic dystrophy type 1, marking a key milestone in the company’s development efforts. Also in 2021, Avidity will advance AOC FSHD into IND-enabling studies and expand its Duchenne muscular dystrophy programs targeting multiple mutations. This collaboration aims to explore AOCs in cardiac applications, furthering Avidity's strategic objectives.
Avidity Biosciences (Nasdaq: RNA) announced that CEO Sarah Boyce will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 12:40 PM PST. The event will be held virtually. A live webcast can be accessed on the company's website, with a replay available for 30 days.
Avidity is focused on developing Antibody Oligonucleotide Conjugates (AOCs™), targeting serious diseases through its proprietary platform. Its lead candidate, AOC 1001, aims to treat myotonic dystrophy type 1, along with programs for various muscle diseases.
Avidity Biosciences (Nasdaq: RNA) has been added to the Nasdaq Biotechnology Index effective December 21, 2020. This index tracks biotechnology and pharmaceutical securities listed on the NASDAQ Stock Market. Avidity focuses on developing a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) to treat serious diseases. Their lead candidate, AOC 1001, targets myotonic dystrophy type 1. The company is headquartered in La Jolla, California, and aims to overcome the limitations of traditional oligonucleotide therapies.
Avidity Biosciences (RNA) reported Q3 2020 financial results, highlighting a strong cash position of $341 million, significantly up from $94.6 million at the end of 2019, thanks to its IPO. Collaboration revenue increased to $1.7 million from $0.7 million year-over-year, while R&D expenses rose to $9.5 million due to advancements in AOC 1001, aimed at treating myotonic dystrophy type 1. The company is focused on launching clinical studies for this therapy and expanding research into new tissues targeted by its innovative AOC platform.
Avidity Biosciences (Nasdaq: RNA) will present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on November 12, 2020, at 8:45 am PST. Sarah Boyce, the President and CEO, will lead the presentation in a virtual format. A live webcast will be available on the company's website, with an archived replay accessible for one year. Avidity is focused on developing innovative oligonucleotide-based therapies, including their lead candidate AOC 1001 for treating myotonic dystrophy type 1, as well as therapies for muscle atrophy and other serious diseases.
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company, will participate in the Chardan 4th Annual Genetic Medicines Conference 2020. The event is scheduled for October 5, 2020, at 12:45 pm PDT, featuring a fireside chat with key executives including CEO Sarah Boyce and CFO Mike MacLean. Additionally, Dr. Arthur Levin will join a panel on Small RNA Therapies on October 6, 2020, at 12:00 pm PDT. The conference will be held virtually, and a live webcast will be available on the company's website with a 90-day replay available.
Avidity Biosciences (Nasdaq: RNA) announced its participation in several virtual scientific meetings to present advancements in its novel Antibody Oligonucleotide Conjugates (AOCs™) platform. Key presentations include:
- TIDES USA 2020 on Sept. 16
- OTS 2020 on Sept. 28
- Next Generation Protein Therapeutics Summit on Nov. 5
- TIDES Europe on Nov. 13
- Neuromuscular Drug Development Summit on Dec. 3
CEO Art Levin highlighted AOC 1001's expected entry into Phase 1/2 trials for myotonic dystrophy type 1, aiming to address serious genetic diseases.
Avidity Biosciences (Nasdaq: RNA) announced a collaboration to support END-DM1, a natural history study aimed at understanding disease progression in myotonic dystrophy type 1 (DM1). The study will enroll approximately 650 participants across the U.S. and Europe, helping inform the development of Avidity's lead program, AOC 1001. This program aims to provide a disease-modifying treatment for DM1 by reducing harmful DMPK mRNA levels. AOC 1001 is scheduled for a Phase 1/2 clinical trial initiation in 2021.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced that CEO Sarah Boyce will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on September 10 at 9:00 am PT. The event will be held virtually, with a live webcast available on Avidity's website. A replay of the chat will be archived for 60 days. Avidity is focused on developing Antibody Oligonucleotide Conjugates (AOCs) aimed at treating serious diseases, including myotonic dystrophy type 1 and other muscle conditions.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
What is Avidity Biosciences, Inc.?
What are Antibody Oligonucleotide Conjugates (AOCs™)?
What is AOC 1001 (Del-desiran)?
What are the key clinical programs of Avidity Biosciences?
What designations has AOC 1044 received?
What is the significance of the MARINA-OLE™ trial?
What other areas is Avidity Biosciences expanding into?
Where is Avidity Biosciences headquartered?
How is Avidity Biosciences funded?
How can I learn more about Avidity Biosciences?
